146 related articles for article (PubMed ID: 32324838)
41. The clinicopathologic patterns of prostatic diseases and prostate cancer in Saudi patients.
Mosli HA; Abdel-Meguid TA; Al-Maghrabi JA; Kamal WK; Saadah HA; Farsi HM
Saudi Med J; 2009 Nov; 30(11):1439-43. PubMed ID: 19882057
[TBL] [Abstract][Full Text] [Related]
42. Trends of prostate cancer incidence and mortality in Shanghai, China from 1973 to 2009.
Qi D; Wu C; Liu F; Gu K; Shi Z; Lin X; Tao S; Xu W; Brendler CB; Zheng Y; Xu J
Prostate; 2015 Oct; 75(14):1662-8. PubMed ID: 26184773
[TBL] [Abstract][Full Text] [Related]
43. Risk of incident benign prostatic hyperplasia in patients with gout: a retrospective cohort study.
Li WM; Pasaribu N; Lee SS; Tsai WC; Li CY; Lin GT; Chuang HY; Tung YC; Tu HP
Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):277-286. PubMed ID: 29858589
[TBL] [Abstract][Full Text] [Related]
44. Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.
Shelton PQ; Ivanowicz AN; Wakeman CM; Rydberg MG; Norton J; Riggs SB; Teigland CM
Urology; 2013 May; 81(5):979-84. PubMed ID: 23523297
[TBL] [Abstract][Full Text] [Related]
45. Recent trends in prostate cancer in Canada.
LeBlanc AG; Demers A; Shaw A
Health Rep; 2019 Apr; 30(4):12-17. PubMed ID: 30994922
[TBL] [Abstract][Full Text] [Related]
46. Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China.
Liu X; Yu C; Bi Y; Zhang ZJ
Public Health; 2019 Jul; 172():70-80. PubMed ID: 31220754
[TBL] [Abstract][Full Text] [Related]
47. National economic and development indicators and international variation in prostate cancer incidence and mortality: an ecological analysis.
Neupane S; Bray F; Auvinen A
World J Urol; 2017 Jun; 35(6):851-858. PubMed ID: 27744614
[TBL] [Abstract][Full Text] [Related]
48. Long-term Trends in Prostate Cancer Incidence by Stage at Diagnosis in Japan Using the Multiple Imputation Approach, 1993-2014.
Saito E; Hori M; Matsuda T; Yoneoka D; Ito Y; Katanoda K
Cancer Epidemiol Biomarkers Prev; 2020 Jun; 29(6):1222-1228. PubMed ID: 32169995
[TBL] [Abstract][Full Text] [Related]
49. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.
Helgstrand JT; Røder MA; Klemann N; Toft BG; Lichtensztajn DY; Brooks JD; Brasso K; Vainer B; Iversen P
Cancer; 2018 Jul; 124(14):2931-2938. PubMed ID: 29723398
[TBL] [Abstract][Full Text] [Related]
50. Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2007 and 2013: status from a Danish primary referral center.
Thomsen FB; Mikkelsen MK; Hansen RB; Krug AH; Glenthøj A; Stattin P; Brasso K
Acta Oncol; 2016 Dec; 55(12):1456-1460. PubMed ID: 27333339
[TBL] [Abstract][Full Text] [Related]
51. Primary cancers before and after prostate cancer diagnosis.
Van Hemelrijck M; Drevin L; Holmberg L; Garmo H; Adolfsson J; Stattin P
Cancer; 2012 Dec; 118(24):6207-16. PubMed ID: 22674346
[TBL] [Abstract][Full Text] [Related]
52. A joinpoint and age-period-cohort analysis of ocular cancer secular trends in Iran from 2004 to 2016.
Abolhosseini M; Khorrami Z; Safi S; Akbari ME; Moshtaghion SM; Mohammadi SF; Kanavi MR; Karimi S
Sci Rep; 2023 Jan; 13(1):1074. PubMed ID: 36658192
[TBL] [Abstract][Full Text] [Related]
53. Descriptive epidemiology of pituitary tumors in the United States, 2004-2009.
Gittleman H; Ostrom QT; Farah PD; Ondracek A; Chen Y; Wolinsky Y; Kruchko C; Singer J; Kshettry VR; Laws ER; Sloan AE; Selman WR; Barnholtz-Sloan JS
J Neurosurg; 2014 Sep; 121(3):527-35. PubMed ID: 24926650
[TBL] [Abstract][Full Text] [Related]
54. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
55. Digoxin lowers the incidence of prostate cancer: A nationwide population-based study.
Lin TP; Fan YH; Chen YC; Huang WJS
J Chin Med Assoc; 2020 Apr; 83(4):377-381. PubMed ID: 32132383
[TBL] [Abstract][Full Text] [Related]
56. [Evolution of the number of incident cases of prostate cancer in France from 2001 to 2012 from 5 hospital centers].
Helfrich O; Crouzet S; Ruffion A; Houlgatte A; Cavillon C; Gerard C; Villers A
Prog Urol; 2015 Mar; 25(3):147-56. PubMed ID: 25481672
[TBL] [Abstract][Full Text] [Related]
57. Trends in United States Prostate Cancer Incidence Rates by Age and Stage, 1995-2012.
Hoffman RM; Meisner AL; Arap W; Barry M; Shah SK; Zeliadt SB; Wiggins CL
Cancer Epidemiol Biomarkers Prev; 2016 Feb; 25(2):259-63. PubMed ID: 26646364
[TBL] [Abstract][Full Text] [Related]
58. Assessing the risk of unsuspected prostate cancer in patients with benign prostatic hypertrophy: a 13-year retrospective study of the incidence and natural history of T1a-T1b prostate cancers.
Tombal B; De Visccher L; Cosyns JP; Lorge F; Opsomer R; Wese FX; Van Cangh PJ
BJU Int; 1999 Dec; 84(9):1015-20. PubMed ID: 10571626
[TBL] [Abstract][Full Text] [Related]
59. Changing Incidence and Stage Distribution of Prostate Cancer in a Lithuanian Population-Evidence from National PSA-Based Screening Program.
Patasius A; Smailyte G
Int J Environ Res Public Health; 2019 Dec; 16(23):. PubMed ID: 31816821
[TBL] [Abstract][Full Text] [Related]
60. Continuing communicable disease burden in Eritrea.
Mufunda J; Nyarango P; Kosia A; Ogbamariam A; Mebrahtu G; Usman A; Gebresillosie S; Goitom S; Araya E; Andemichael G; Gebremichael A
S Afr Med J; 2006 Mar; 96(3):221-4. PubMed ID: 16607433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
